General Spectrum of Activity
Cytomegalovirus (CMV) prophylaxis in allogenic hematopoietic stem cell transplant (HSCT) seropositive patients.
CMV treatment (requires approval by Infectious Diseases).
Serum creatinine, especially in patients with CrCl < 50 mL/min receiving IV formulation.
Moderate inhibitor CYP3A4 and inhibitor of OATP1/3 transporters.
Significant drug interactions exist which may warrant dose or frequency adjustments or avoidance. Consult drug interaction database prior to initiation.
Dose reduce to 240mg daily during coadministration with cyclosporine.
Antimicrobial class: anti-CMV antiviral - DNA terminase complex inhibitor
Pregnancy: Fetal risk cannot be ruled out
Average serum half life: 12 hours
CSF penetration: Not available